Clinical trial registry record

Ranibizumab and the Risk of Arterial Thromboembolic Events

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Terminated.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated May 19, 2015.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01319188
Last registry update
May 19, 2015
Status
Terminated
Phase
Phase 4
Sponsor
Ural State Medical University
Enrollment
380
Countries
Netherlands, Russia
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
RANDOMIZED · PARALLEL · SCREENING · DOUBLE
Evidence population
Human clinical study registration
Participants
380
Population
ALL · 50 Years to 90 Years
Duration
2010-06-01 to 2015-04-01
Intervention
0.5 mg of ranibizumab; 0.5 mg of ranibizumab + photodynamic therapy; Sham injection
Comparator
0.5 mg of ranibizumab; injection + photodynamic therapy
Outcomes measured
Arterial thromboembolic events rate — at month 6, 12 and 24; Serum concentration of ranibizumab — at month 6, 12 and 24; Serum VEGF — at month 6, 12 and 24; Mean change in visual acuity (letters) — at month 6, 12 an 24; Coronary and/or cerebral stenting, and/or CABG rate — at month 6, 12 an 24; Total cholesterol — at month 6, 12 and 24; Systolic blood pressure — at month 6, 12 and 24; NYHA (New York Heart Association) functional class of heart failure — at month 6, 12 and 24; Diabetes mellitus morbidity — at month 6, 12 and 24; Serum fibrinogen — at month 6, 12 and 24; Serum C-RP — at month 6, 12 and 24; Serum D-dimer — at month 6, 12 and 24
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON